{"resourceType": "Library", "id": "179632", "meta": {"profile": ["http://hl7.org/fhir/uv/ebm/StructureDefinition/systematic-review-excluded-studies"], "versionId": "2", "lastUpdated": "2023-11-26T22:51:21.545Z"}, "url": "https://fevir.net/resources/Library/179632", "title": "SystematicReviewExcludedStudies: ADT and Docetaxel vs. ADT alone for metastatic hormone-naive prostate cancer - Brian S. Alper", "status": "active", "type": {"coding": [{"system": "http://terminology.hl7.org/CodeSystem/library-type", "code": "asset-collection", "display": "Asset Collection"}]}, "subjectReference": {"reference": "Group/179619", "type": "Group", "display": "SystematicReviewEligibilityCriteria: ADT and Docetaxel vs. ADT alone for metastatic hormone-naive prostate cancer"}, "date": "2023-11-26T18:15:27.442Z", "publisher": "Computable Publishing LLC", "contact": [{"telecom": [{"system": "email", "value": "support@computablepublishing.com"}]}], "description": "11 excluded studies", "useContext": [{"code": {"system": "https://fevir.net/resources/CodeSystem/179423", "code": "evidence-communication", "display": "Evidence Communication"}, "valueCodeableConcept": {"coding": [{"system": "https://fevir.net/resources/CodeSystem/179423", "code": "SystematicReviewExcludedStudies", "display": "SystematicReviewExcludedStudies"}]}}], "copyright": "https://creativecommons.org/licenses/by-nc-sa/4.0/", "relatedArtifact": [{"type": "derived-from", "resourceReference": {"reference": "Citation/179613", "type": "Citation", "display": "27308831 Efficacy and Safety of Combined Androgen Deprivation Therapy (ADT) and Docetaxel Compared with ADT Alone for Metastatic Hormone-Naive Prostate Cancer: A Systematic Review and Meta-Analysis."}}, {"type": "contains", "classifier": [{"text": "Different comparison (ADT versus ADT plus estramustine)"}], "resourceReference": {"reference": "Citation/179628", "type": "Citation", "display": "14706014 Chemohormonal therapy as primary treatment for metastatic prostate cancer: a randomized study of estramustine phosphate plus luteinizing hormone-releasing hormone agonist versus flutamide plus luteinizing hormone-releasing hormone agonist."}}, {"type": "contains", "classifier": [{"text": "Different comparison (ADT versus ADT plus chemotherapy without docetaxel)"}], "resourceReference": {"reference": "Citation/179631", "type": "Citation", "display": "19029421 Phase III trial of androgen ablation with or without three cycles of systemic chemotherapy for advanced prostate cancer."}}, {"type": "contains", "classifier": [{"text": "Different comparison (ADT versus ADT plus radiotherapy)"}], "resourceReference": {"reference": "Citation/179627", "type": "Citation", "display": "19091394 Endocrine treatment, with or without radiotherapy, in locally advanced prostate cancer (SPCG-7/SFUO-3): an open randomised phase III trial."}}, {"type": "contains", "classifier": [{"text": "Different comparison (ADT versus ADT plus radiotherapy)"}], "resourceReference": {"reference": "Citation/179626", "type": "Citation", "display": "22056152 Combined androgen deprivation therapy and radiation therapy for locally advanced prostate cancer: a randomised, phase 3 trial."}}, {"type": "contains", "classifier": [{"text": "Different comparison (ADT versus ADT plus radiotherapy)"}], "resourceReference": {"reference": "Citation/179625", "type": "Citation", "display": "22502942 Addition of radiotherapy to long-term androgen deprivation in locally advanced prostate cancer: an open randomised phase 3 trial."}}, {"type": "contains", "classifier": [{"text": "Nonrandomized"}], "resourceReference": {"reference": "Citation/179629", "type": "Citation", "display": "23604530 A phase II trial of androgen deprivation therapy (ADT) plus chemotherapy as initial treatment for local failures or advanced prostate cancer."}}, {"type": "contains", "classifier": [{"text": "Neoadjuvant treatment"}], "resourceReference": {"reference": "Citation/179624", "type": "Citation", "display": "24598155 Long-term results of a phase II study with neoadjuvant docetaxel chemotherapy and complete androgen blockade in locally advanced and high-risk prostate cancer."}}, {"type": "contains", "classifier": [{"text": "Nonrandomized"}], "resourceReference": {"reference": "Citation/179622", "type": "Citation", "display": "26002607 Should docetaxel be standard of care for patients with metastatic hormone-sensitive prostate cancer? Pro and contra."}}, {"type": "contains", "classifier": [{"text": "High-risk localized prostate cancer"}], "resourceReference": {"reference": "Citation/179621", "type": "Citation", "display": "26028518 Androgen deprivation therapy plus docetaxel and estramustine versus androgen deprivation therapy alone for high-risk localised prostate cancer (GETUG 12): a phase 3 randomised controlled trial."}}, {"type": "contains", "classifier": [{"text": "Locally advanced or metastatic (without metastatic subgroup analysis)"}], "resourceReference": {"reference": "Citation/179630", "type": "Citation", "display": "26092557 Feasibility study of a randomized controlled trial comparing docetaxel chemotherapy and androgen deprivation therapy with sequential prostatic biopsies from patients with advanced non-castration-resistant prostate cancer."}}, {"type": "contains", "classifier": [{"text": "Nonrandomized"}], "resourceReference": {"reference": "Citation/179623", "type": "Citation", "display": "23452809 Long-term follow-up of a phase II trial of chemotherapy plus hormone therapy for biochemical relapse after definitive local therapy for prostate cancer."}}], "identifier": [{"type": {"text": "FEvIR Object Identifier", "coding": [{"system": "http://terminology.hl7.org/CodeSystem/v2-0203", "code": "ACSN", "display": "Accession ID"}]}, "system": "https://fevir.net", "value": "179632", "assigner": {"display": "Computable Publishing LLC"}}], "author": [{"name": "Brian S. Alper"}]}